Results of the comparative analysis of the Idylla platform vs TruSight Tumor26 NGS
| Cancer type | Idylla | TruSight Tumor26 NGS | Discordances |
| Melanoma (BRAF) | |||
| Mutants (n) | 8 of 13 | 8 of 13 | 0 |
| Type of mutation | Val600Glu (n=7) Val600Arg (n=1) | Val600Glu (n=7) Val600Arg (n=1) | |
| Idylla performance analysis | 100% overall percentage of agreement (κ=1.00; 95% CI 1.0) PPA: 100% (95% CI 1.0); NPA: 100% (95% CI 1.0) | ||
| Metastatic colon carcinoma (KRAS) | |||
| Mutants (n) | 9 of 18 | 8 of 18 | 1* |
| Type of mutation | Gly12Asp (n=2) Gly12Ala (n=1) Gly12Val (n=1) Gly13Asp (n=1) Gly12Cys (n=1) Gln61Arg/Leu (n=1) Ala146Thr/Val/Pro (n=1) Gln61His (n=1)* | Gly12Asp (n=2) Gly12Ala (n=1) Gly12Val (n=1) Gly13Asp (n=1) Gly12Cys (n=1) Gln61Arg (n=1) Ala146Thr (n=1) | |
| Idylla performance analysis | 94% agreement (κ=0.883; 95% CI 0.661 to 1.0) PPA: 100% (95% CI 1.0); NPA: 90% (95% CI 0.80 to 1.0) | ||
| Non-small cell lung cancer (EGFR) | |||
| Mutants (n) | 5 of 17 | 6 of 17 | 1† |
| Type of mutation | ins_exon 20 (n=1) del_exon 19 (n=1) del_Thr790Met (n=1) Gly719X (n=1) Leu861Gln (n=1) | ins_exon 20 (n=1) del_exon 19 (n=1) del_Thr790Met (n=1) Gly719Ala (n=1) Leu861Gln (n=1) Uncommon mutation (n=1)† | |
| Idylla performance analysis | 94% agreement (κ=0.866; 95% CI 0.614 to 1.0) PPA: 83% (95% CI 0.65 to 1.0); NPA: 100% (95% CI 1.0) | ||
*KRAS mutation analysis performed on Cobas 4800 by a blinded third party.
†c.2217_2234dup, p.(Ile740_Lys745dup) is not included in the Idylla panel.
κ, Cohen’s kappa coefficient; NPA, negative percentage of agreement; PPA, positive percentage of agreement.